Laman UtamaAMLX • NASDAQ
add
Amylyx Pharmaceuticals Inc
$3.82
Selepas Waktu Dagangan:(0.00%)0.00
$3.82
Tutup: 16 Apr, 4:01:43 PTG GMT-4 · USD · NASDAQ · Penafian
Tutup sebelumnya
$3.88
Julat hari
$3.79 - $3.93
Julat tahun
$1.58 - $7.26
Permodalan pasaran
338.46J USD
Bilangan Purata
813.47K
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Hasil | -665.00K | -100.61% |
Perbelanjaan pengendalian | 53.30J | 2.03% |
Pendapatan bersih | -37.55J | -893.62% |
Margin untung bersih | 5.65K | 129,395.87% |
Pendapatan bagi setiap syer | -0.55 | -885.71% |
EBITDA | -40.49J | -1,911.81% |
Kadar cukai berkesan | 1.66% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 176.50J | -52.47% |
Jumlah aset | 193.63J | -62.58% |
Jumlah liabiliti | 28.87J | -65.64% |
Jumlah ekuiti | 164.76J | — |
Syer tertunggak | 88.60J | — |
Harga kepada buku | 1.62 | — |
Pulangan pada aset | -45.75% | — |
Pulangan pada modal | -55.61% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -37.55J | -893.62% |
Tunai daripada operasi | -59.01J | -535.45% |
Tunai daripada pelaburan | 64.98J | 210.54% |
Tunai daripada pembiayaan | 110.00K | -52.17% |
Perubahan bersih dalam tunai | 5.56J | -84.10% |
Aliran tunai bebas | -45.65J | -239.09% |
Perihal
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
Diasaskan
2013
Tapak web
Pekerja
123
